Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Press Releases
Welcome to our press release archive. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
Latest Press Releases
Citeline and Norstella Unite to Offer Life Sciences Clients a Full Suite of Commercial and Clinical Solutions
The new organization will help life sciences companies improve strategic decision-making and accelerate the mission of smoothing access to therapy from pipeline to…
2022年 希少疾病用医薬品動向 Evaluate オーファンドラッグ 2022 レポート 日本語版リリース
東京、日本－2022年5月26日 – 製薬業界における戦略策定や事業性評価に不可欠な信頼性の高いマーケット情報及び分析を提供するEvaluate（エバリュエート本社：ロンドン）は、2022年4月に発行した希少疾病用医薬品動向レポート 「オーファンドラッグ 2022 レポート」（原文：英語）の日本語版をリリースしました。
Evaluate appoints Matthew Wright as Chief Financial Officer
London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today…
Browse the archive
Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Worldwide Prescription Drug Sales Accelerate To $1.2 Trillion By 2024, As Unmet Need Drives Annual Compound Growth To Over 6%
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Worldwide Orphan Drug Sales Are Forecast To Grow At A Cagr Of 11.3% From 2018 To 2024, Double The Rate Forecast For The Non-Orphan Drug Market
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
Fast Pace Of Drug And Device Approvals In 2017 Signals Wider Sector Health For Biopharma But Medtech Companies Struggle
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
Uptick In M&A Activity And Investor Cash Expected To Re-Invigorate Pharma And Biotech In 2018
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
Worldwide Medtech Sales Forecast To Reach $522 Billion By 2022 With A Cagr Of 5.1% Between 2016 And 2022
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
Biopharma Stages A Strong Recovery Over The First Half Even As M&A Deals Disappoint, While Unprecedented Amounts Of Money Flow In Medtech But Not Towards Smaller Innovators
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Japanese Pharmaceutical Market Set To Grow 3.3% (Cagr) Between 2017 And 2022, Significantly Lower Than The Worldwide Outlook (6.5% Cagr)
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
